African Americans have a high incidence of heart failure (HF). Limited retrospective observational subgroup analyses of patients with left ventricular systolic dysfunction (LVSD) suggest marginal benefit of angiotensinconverting enzyme inhibitors in the prevention of HF hospitalizations or total mortality in African Americans.
Heart failure (HF) and/or left ventricular systolic dysfunction (LVSD) frequently complicate acute myocardial infarction (MI), and significantly worsen the prognosis of patients with coronary heart disease (CHD) (1) . African Americans with CHD have the highest mortality rates and have shown slower declines in CHD mortality relative to white Americans (2) . African Americans also have disproportionately higher rates of HF, and the diagnosis carries higher morbidity (3) (4) (5) . Compared with white patients, overall mortality among African Americans with HF is higher. Because the incidence of MI in African Americans is thought to be lower than in white patients, a higher incidence of hypertension is often cited as the dominant cause of HF.
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Several large randomized controlled trials have shown that angiotensin-converting enzyme (ACE) inhibitors reduce mortality and other adverse outcomes in the treatment of acute MI with LVSD (6 -12) . The efficacy of neurohormonal antagonists, specifically ACE inhibitors, in African-American patients has been questioned given several clinical trials showing a diminished effect on blood pressure and prevention of HF in African-American patients treated with ACE inhibitors compared with white Americans (13) . Additionally, retrospective analyses have suggested that ACE inhibitors are less effective in African Americans with chronic HF based on higher hospitalization rates on treatment for African Americans compared with white Americans (4, 14) . Prior studies have not examined the effect of angiotensin receptor blockers (ARBs) or the combination of ACE inhibitors and ARBs in African-American HF patients relative to similarly treated white Americans. The VALIANT (VALsartan In Acute myocardial iNfarcTion trial) studied 14,703 patients and compared the effectiveness of an ACE inhibitor, ARB, and their combination among patients with MI complicated by LVSD, HF, or both (12) . Acute MI was diagnosed by a typical clinical presentation and/or electrocardiographic changes and abnormal cardiac markers. For overall mortality and the rate of death from cardiovascular causes, reinfarction, or hospitalization for HF, valsartan was as effective as captopril. There was no added benefit for combining the drugs.
The goals of this analysis were to assess the effect of captopril, valsartan, or captopril plus valsartan on multiple outcomes as a function of race. The specific outcomes of interest include: all-cause mortality, cardiovascular mortality, HF hospitalizations, recurrent MI, stroke, adverse events, and medication discontinuation.
Methods
Study design. The methods for this trial have been previously described, and the main results were reported (12, 15) . Briefly, this was a randomized, double-blind trial conducted in 24 countries. The entire trial included 14,703 patients. The primary outcome was death from any cause. Valsartan was compared with captopril and valsartan plus captopril for the primary end point of overall mortality and the secondary cardiovascular end points. If valsartan was not superior or inferior to captopril, a noninferiority analysis (using both intention-to-treat and per-protocol analyses) was planned to test the null hypothesis that valsartan and captopril were comparable for the primary end point. There was no difference in total mortality or the combined cardiovascular end point for valsartan compared with captopril or valsartan plus captopril versus captopril. Thus, valsartan was as effective as captopril and combination therapy offered no added benefits, but did increase the rate of adverse events.
This subset analysis includes 3,730 patients (3,390 white and 340 African-American patients) enrolled in the U.S. Men and women Ն18 years of age who sustained an acute MI complicated by clinical or radiographic signs of HF and/or evidence of LVSD by echocardiography, contrast angiography, or radionuclide ventriculography were enrolled. Exclusion criteria included: systolic blood pressure Ͻ100 mm Hg, serum creatinine Ͼ2.5 mg/dl, previous intolerance or contraindication to ACE inhibitors or ARBs, significant valvular heart disease, or a concomitant disease severely limiting life expectancy. All patients were required to provide written informed consent. The VALIANT study used 4 race/ethnicity categorizations that were obtained at enrollment: white/Caucasian, black/African American, Asian, and other/unknown. Race was self-reported, and only patients identified as African American or white were included in this analysis.
Consenting eligible patients were randomly assigned 1:1:1 to treatment with valsartan, captopril, or a combination of captopril plus valsartan. The starting doses were valsartan 20 mg, captopril 6.25 mg, or valsartan 20 mg plus captopril 6.25 mg once daily. The dose could be titrated up to valsartan 160 mg twice daily, captopril 50 mg 3 times daily, or valsartan 80 mg twice daily plus captopril 50 mg 3 times daily. The doses used in each group could be titrated according to the patient's clinical status. A clinical end point committee blinded to treatment assignment adjudicated primary end points. A single independent data and safety monitoring board and the institutional review board or ethics committee at each participating site approved the protocol. Statistical analysis. All statistical analyses were performed at the Duke Clinical Research Institute. African-American patients were compared with white American patients on 3-year clinical outcomes of all-cause mortality, cardiovascular mortality, hospitalization for HF, recurrent MI, and stroke. The null hypothesis was that there is no difference between African-American and white patients on a given 3-year clinical outcome.
Comparison of baseline characteristics and adverse events between African Americans and white Americans were carried out using a Pearson chi-square or Cochran-MantelHaenszel chi-square test, and a Wilcoxon rank sum test for categorical and continuous data, respectively. Clinical outcomes at 3 years were analyzed using Cox regression models stratified by race. Cumulative event rates through 3 years were estimated for both African Americans and white Americans, after adjustment for baseline characteristics.
Stepwise selection was used to choose baseline characteristics and create a parsimonious model for each clinical outcome. A p value of 0.10 was required for a variable to enter and stay in the final model. Longitudinal analysis was carried out to examine the effects of covariates to variables of interest over time. Trajectories were plotted for visual The list of control variables for each clinical outcome is reported in the Online Appendix. Standard errors of adjusted event rates were estimated by bootstrapping from the original data with 500 resamples of the entire cases of data. Differential treatment effects on African Americans versus white Americans were tested by interactions between race and treatments adjusting for baseline characteristics.
Continuous variables were summarized as medians with 25th and 75th percentiles, and categorical variables as frequencies and percentages. For a single comparison, a p value of 0.05 was considered statistically significant evidence to reject a null hypothesis. For multiple comparisons, the significance level was adjusted by the Bonferroni method.
The SAS software package (version 8, SAS Institute Inc., Cary, North Carolina) was used for data analysis; SAS Jackboot macro (SAS Institute, Inc.) was used for bootstrapping standard errors.
Results
Baseline characteristics. Mean baseline total creatine phosphokinase and troponin I were not significantly different between African-American and white patients. African Americans were younger, more often female, and also more likely than white Americans to have a history of diabetes mellitus, chronic HF, and hypertension (Table 1) . Moreover, African Americans had a lower estimated glomerular filtration rate (eGFR), higher systolic and diastolic blood pressures, faster heart rate, and higher Killip class. Conversely, white patients were more likely to have been previously hospitalized, to have undergone prior percutaneous coronary intervention (PCI), and to have a history of unstable angina. During the index hospitalization, HF and renal insufficiency were observed in more African Americans than white Americans.
African-American patients (84.1%) were as likely as white patients (88.6%) to undergo coronary angiography after acute MI. Among African Americans, the percentage of the number of diseased coronary vessels was 5.9% (none), 30.4% (single), 24.5% (double), and 39.2% (triple). The percentage among white Americans was 1.7% (none), 30.8% (single), 27.2% (double), and 40.3% (triple). However, after adjusting for the presence of single-vessel, double-vessel, and triple-vessel disease, African Americans were less likely than white Americans to receive PCI (p ϭ 0.003) or coronary artery bypass grafting (CABG) (p ϭ 0.021).
African Americans were more likely to be treated with an ACE inhibitor, long-acting nitrates, insulin, and nonpotassium-sparing diuretics (Table 2) . White Americans were more likely to be treated with antiplatelet therapies (other than aspirin) and oral anticoagulants. At 1 year of follow-up, comparisons by race of concomitant pharmacotherapies showed significant differences in several evidencebased medications. African Americans were more often treated with beta-blockers, calcium-channel blockers, nonpotassium-sparing diuretics, long-acting nitrates, and other vasodilators. White Americans were more likely to be treated with aspirin, statins, or other lipid modulating therapies (Table 2) . Outcomes. There were no significant differences in the adjusted 3-year rates of all-cause mortality (22.1% for African Americans vs. 20.3% for white Americans; p ϭ 0.45) or cardiovascular mortality (18.4% for African Americans vs. 16.7% for white Americans; p ϭ 0.31) (Fig. 1) . The recurrent MI rate at 3 years was similar between African Americans and white Americans. There was a trend toward higher rates of HF hospitalizations for AfricanAmerican patients compared with white Americans at 3 years (p ϭ 0.09). The stroke rate for African Americans was approximately twice as high as for white Americans (8.0% vs. 3.7%; p ϭ 0.06). The outcomes by race for all-cause (Fig. 2) . Similarly, for the outcomes of cardiovascular mortality, hospitalization for HF, recurrent MI, and stroke, there were no differences among African-American patients treated with any of the 3 medical regimens. Adverse events and medication discontinuation. White patients were more likely than African Americans to experience hypotension (32.8% vs. 20.9%; p Ͻ 0.0001). There were no racial differences in the incidence of dry cough, which occurred in approximately 19% of all patients (20.2% for white patients vs. 18.8% for African Americans; p ϭ 0.6), most of which was treated with captopril. Angioedema was rare; however, among patients treated with captopril, African Americans were almost 2 times more likely than white patients to develop angioedema, a result that was not statistically significant (1.2% for white patients vs. 2.1% for African Americans; p ϭ 0.2). Adverse events led to discontinuation of treatment in Ͻ11% of the population treated. Angioedema was the most common reason for discontinuing captopril among African-American patients. Dry cough was the most prevalent adverse event that led to medication discontinuation in white Americans. There was a nonstatistically significant trend for the development of renal dysfunction in African-American patients for all treatments compared with white patients (12.4% for white patients vs. 15.9% for African Americans; p ϭ 0.07). A longitudinal analysis showed that diuretic use over time and baseline renal insufficiency were strongly The adjusted cardiovascular event rates are not significantly different between African Americans and white patients. CHF ϭ congestive heart failure; CI ϭ confidence interval; CV ϭ cardiovascular; MI ϭ myocardial infarction.
Figure 2
Cumulative All-Cause Mortality Rate of African Americans on Different Randomized Treatments
There was no difference in all-cause mortality according to assigned therapy.
Concomitant Medications
Before Randomization and at 1 Year associated with renal dysfunction during the trial (p Ͻ 0.0001 for both factors). In addition to having more renal insufficiency at baseline, African Americans had a significantly higher number of individuals who developed renal insufficiency from the post-qualifying MI to randomization compared with white patients; the absolute difference was 5.58%. Furthermore, there were a significantly greater number of African Americans taking diuretics overall as well (p Ͻ 0.001). African Americans have significantly (p Ͻ 0.0001) higher rates of diuretic use before discontinuation of study drug (63.3%) compared with white patients (47.2%). African Americans were more likely than white patients to develop renal dysfunction and hyperkalemia requiring valsartan discontinuation (Table 3) . After adjusting for chronic renal insufficiency (eGFR Ͻ60 ml/min/1.73 m 2 ) at baseline, the difference between African Americans and white American patients on developing renal dysfunction during the study was not significant (p ϭ 0.1346). However, the difference between African Americans and white Americans on discontinuing valsartan treatment for renal causes (Table 3) persisted (p Ͻ 0.0001) after adjusting for baseline renal insufficiency.
Discussion
In a high-risk population with HF or LVSD after an acute MI, African-American patients treated with captopril, valsartan, or both had similar clinical outcomes to white American patients, after adjusting for differences in comorbidities. Despite having significantly more coronary risk factors and more markers of poor outcome post-infarction, African Americans were less likely to be revascularized percutaneously or surgically after MI. This disparity remained after adjusting for the extent of coronary artery disease. The differential use of revascularization procedures according to race has been extensively reported and is associated with worse outcomes in several studies (16 -19) . Because there was a trend toward higher rates of HF hospitalizations for African Americans compared with white Americans at 3 years, we can only speculate as to whether this is attributable to treatment with calciumchannel blockers, more coronary risk factors and poor post-infarction outcome markers, or fewer revascularization procedures. Prior studies. Conflicting results from several clinical trials involving pharmacological blockade of the renin-angiotensinaldosterone system have led to questions about the efficacy of these agents in African Americans. In the AASK (African American Study of Kidney Disease and Hypertension), patients treated with the ACE inhibitor ramipril as the first drug of combination therapy, as compared with a beta-blocker or calcium antagonist as initial therapy, had a decrease in the progression of their renal disease (20, 21) . The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) reported African Americans had more strokes, more HF, and less blood pressure reduction on an ACE inhibitor compared with a diuretic, but not a higher total mortality (13) . In the LIFE (Losartan Intervention For End Point Reduction in Hypertension) study, losartan was less effective than atenolol as a component of antihypertensive therapy among African Americans in reducing fatal and nonfatal strokes (22) . Retrospective analyses of 2 heart failure trials concluded that ACE inhibitors were less effective in African Americans (14, 23) . In the V-HeFT (VasodilatorHeart Failure Trial) II study, enalapril decreased mortality in white patients, but not in African-American patients (14) . In the SOLVD (Studies Of Left Ventricular Dysfunction) study, African-American patients had a poorer prognosis and did not have a reduction in total mortality or hospitalization for HF with enalapril compared with placebo (23) . Subsequent reanalysis of the SOLVD dataset that adjusted for ventricular function was able to show only a weak nonsignificant trend toward excess mortality, and a persistent trend in increased hospitalizations for HF among African-American patients (4) . There have been a number of trials with ACE inhibitors conducted in the post-infarction setting (6 -10,24 -26) . However, only 1 trial, the SAVE (Survival And Ventricular Enlargement) study, included at least 125 African-American patients (27) . Unfortunately, the number of African-American Reasons Leading to Discontinuation by Treatment and Race Table 3 Reasons Leading to Discontinuation by Treatment and Race *Includes patients who actually received any study medication. †Symptomatic hypotension is defined as 1 of the following: hypotension (including first-dose hypotension) accompanied by symptoms (e.g., dizziness, faintness, diaphoresis) or persistent hypotension leading to dose reduction, temporary interruption, or permanent discontinuation of study medication. ‡The difference between African Americans and white patients was significant at p Ͻ 0.05. AA ϭ African American; WA ϭ white American.
